Related Experiment Video
Updated: Jul 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel
Allan Bybeck Nielsen1, Louise Bochsen, Daniel A Steinbrüchel
1Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark. allan@bybeck.dk
Insights
Off-Pump Coronary Artery Bypass (OPCAB) surgery may cause temporary hypercoagulability. Clopidogrel showed increased platelet inhibition post-OPCAB, but further research is needed to confirm its clinical benefit.
Area of Science:
- Cardiovascular Surgery
- Thrombosis and Hemostasis
Background:
- Off-Pump Coronary Artery Bypass (OPCAB) surgery is associated with concerns regarding hypercoagulability.
- Standard acetylsalicylic acid prophylaxis may be insufficient in the early weeks following OPCAB.
Purpose of the Study:
- To investigate the effectiveness of clopidogrel in managing hypercoagulability after OPCAB surgery.
- To assess platelet inhibition and hypercoagulability markers in patients undergoing OPCAB.
Main Methods:
- A randomized trial involving 29 patients assigned to clopidogrel (75 mg) or a control group for 30 days post-OPCAB.
- Thrombelastography (TEG) and platelet inhibition assays were used to evaluate coagulation status over a 2-month follow-up period.
Main Results:
- A significant increase in TEG maximum amplitude (hypercoagulability) was observed 5 days post-surgery in both groups.
- Platelet inhibition was significantly higher in the clopidogrel group (34.1%) compared to the control group (11.0%) at 1 month.
Conclusions:
- Hypercoagulability post-OPCAB is transient, resolving by 1 month.
- No immediate clinical adverse effects of this transient hypercoagulability were observed.
- Further studies are required to determine the optimal antithrombotic strategy, including the role of clopidogrel, after OPCAB.
Objective:
Data on graft patency after Off-Pump Coronary Artery Bypass (OPCAB) suggest that the incidence of early graft closure is not increased compared to conventional coronary artery bypass surgery. However, hypercoagulability following OPCAB is still of concern, and acetylsalicylic acid as thromboembolic prophylaxis might be insufficient in the first weeks following OPCAB surgery.
Design:
Twenty nine patients were randomly assigned to+/- 75 mg of clopidogrel until 30 days after OPCAB surgery. The follow-up time was 2 months including standard blood samples and thrombelastography (TEG) with a specific platelet inhibition assay, which was evaluated as a part of the study.
Results:
In both groups a significant increase in TEG maximum amplitude was found 5 days after surgery. Platelet inhibition showed great variations but was significantly increased in the clopidogrel group (34.1%) vs. control group (11.0%) after 1 month.
Conclusion:
Hypercoagulability was seen 5 days after OPCAB and could not be demonstrated after 1 month. No clinical effects of the hypercoagulability were observed, and further research is needed to determine if clopidogrel should be recommended after OPCAB.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
